What's atypical about atypical antipsychotic drugs?
- PMID: 15018839
- DOI: 10.1016/j.coph.2003.09.010
What's atypical about atypical antipsychotic drugs?
Abstract
Atypical antipsychotic drugs, by definition, differ from typical antipsychotic agents in producing significantly fewer extrapyramidal symptoms and having a lower risk of tardive dyskinesia in vulnerable clinical populations at doses that produce comparable control of psychosis. The atypical drugs differ from the typicals in their mechanism of action, but not all share the same mechanism. Many, but not all, atypicals have been found to improve cognitive function, which could be their most important advantage with regard to efficacy. Clozapine, the prototype of these agents, has been found to improve delusions and hallucinations in patients who fail to respond to other antipsychotic drugs, and to reduce the risk of suicide. These agents have been found to increase cortical dopamine and acetylcholine release, as well as have a variety of effects on the glutamatergic system not shared by the typical agents. Effects on neuronal survival and plasticity, together with decreased neurotoxicity, might also contribute to their clinical advantage over typical neuroleptic drugs.
Similar articles
-
Role of serotonin in the action of atypical antipsychotic drugs.Clin Neurosci. 1995;3(2):64-75. Clin Neurosci. 1995. PMID: 7583621 Review.
-
In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems.Prog Brain Res. 2008;172:177-97. doi: 10.1016/S0079-6123(08)00909-6. Prog Brain Res. 2008. PMID: 18772033 Review.
-
New drugs for schizophrenia: an update for family physicians.Am Fam Physician. 1997 Sep 15;56(4):1149-56, 1159-60. Am Fam Physician. 1997. PMID: 9310066 Review.
-
Differential effects of clozapine versus other antipsychotics on clinical outcome and dopamine release in the brain.Essent Psychopharmacol. 2005;6(2):73-90. Essent Psychopharmacol. 2005. PMID: 15765792 Review.
-
New drugs for the treatment of schizophrenia.Psychiatr Clin North Am. 1993 Jun;16(2):365-85. Psychiatr Clin North Am. 1993. PMID: 8101373 Review.
Cited by
-
Current controversies and future perspectives on treatment of intensive care unit delirium in adults.World J Crit Care Med. 2019 Jun 12;8(3):18-27. doi: 10.5492/wjccm.v8.i3.18. eCollection 2019 Jun 12. World J Crit Care Med. 2019. PMID: 31240172 Free PMC article. Review.
-
Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options.CNS Drugs. 2006;20(6):477-505. doi: 10.2165/00023210-200620060-00004. CNS Drugs. 2006. PMID: 16734499 Review.
-
A genome-wide RNAi screen in Caenorhabditis elegans identifies the nicotinic acetylcholine receptor subunit ACR-7 as an antipsychotic drug target.PLoS Genet. 2013;9(2):e1003313. doi: 10.1371/journal.pgen.1003313. Epub 2013 Feb 28. PLoS Genet. 2013. PMID: 23468647 Free PMC article.
-
Integrated approaches to understanding antipsychotic drug action at GPCRs.Curr Opin Cell Biol. 2014 Apr;27:56-62. doi: 10.1016/j.ceb.2013.11.002. Epub 2013 Dec 14. Curr Opin Cell Biol. 2014. PMID: 24680431 Free PMC article. Review.
-
WAY-163909, a 5-HT2C agonist, enhances the preclinical potency of current antipsychotics.Psychopharmacology (Berl). 2009 May;204(1):37-48. doi: 10.1007/s00213-008-1433-z. Epub 2008 Dec 20. Psychopharmacology (Berl). 2009. PMID: 19107466
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical